🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0

Recruitingn/aAges 18 Years - 90 YearsMaleUniversity of Milano Bicocca
NCT07407608 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy tissues is critically assessed with fulfillment of strict constraints and dose distribution is accomplished using image guidance and tracking tools. In the present trial, intermediate unfavorable and selected high-risk organ-confined prostate cancer patients will undergo Single Dose Radiation Therapy (SDRT) With Focal Boost to the MRI-defined Macroscopic Tumor Volume by means of image-guided volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures. Androgen Deprivation Therapy (ADT) type and duration has been set as per standard of care, in accordance with current recommendations and guid

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically proven prostate adenocarcinoma; * Intermediate and High risk disease, as per the NCCN definition; * a PI-RADS 3-5 dominant intraprostatic lesion on multiparametric MRI (mpMRI); * N0M0 at staging with standard techniques (Bone Scan and Abdominal CT) or (preferably) PSMA PET-CT; * World Health Organization performance status 0-1; * Life expectancy of \> 5 years, in the opinion of the investigator; * IPSS score must be ≤ 15 (alpha blockers allowed); * Prostate gland volume ≤100 g as estimated by computed tomography (CT), ultrasound, or MRI. Exclusion Criteria: * ≥T3b disease according to the 8th AJCC classification; * PSA\>20 ng/ml; * Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy) or transurethral resection; * Previous radiotherapy to the pelvis; * Presence of a periurethral dominant lesion; * Previous invasive malignancy unless disease free for a minimum of 5 years; * Active Crohn's Disease or Ulcerative Colitis; * Presence of hip prostheses.
💊

What it tests

  • SBRT
  • SDRT
📍

Where

1 site
Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy